Pharmaceuticals, Biotechnology & Life Sciences

Mirum Pharma reports maralixibat hits primary endpoint in cholestatic liver disease trial, paving way for Phase III EXPAND data and investor insights.

Discover how AstraZeneca’s new US R&D hub, stellar investor returns, and phase‑III results for efzimfotase alfa shape its 2026 strategy and market outlook.

Discover why KARDIGAN INC’s stock swings from $27 to $12, its $1.37B market cap, and a negative P/E ratio—what it means for investors in health‑care.

Discover how Formycon AG’s biosimilar expertise positions it to thrive as drug patents expire, driving biotech growth and cost‑effective pharma solutions.

Biofrontera AG: German biopharma leader driving dermatological drug & medical cosmetic innovation, strong valuation & global reach.

Capricor Therapeutics pursues breakthrough therapies for Duchenne muscular dystrophy, navigating biotech volatility while driving innovation and patient hope.

GSK invests $800 million in a new Pennsylvania hub and partners with AI firm Chai Discovery, boosting U.S. manufacturing, jobs, and drug‑discovery speed.

Abivax SA leads biotech innovation with Phase II trials for HIV, hepatitis B, and emerging virus therapies, boosting global health outcomes.

Satellos Bioscience, a Toronto‑based biotech, is pioneering skeletal muscle regeneration drugs that boost the body’s own repair, aiming to transform treatment for severe muscle disorders.

Explore Zentalis Pharmaceuticals’ journey to develop groundbreaking small‑molecule cancer drugs, its volatile Nasdaq performance, and what it means for investors and patients alike.